Nanobiotix (id:10860 NANO)
3.10 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/28/2024 1:52:54 AM)
Exchange closed, opens in 7 hours 7 minutes
-2.21 EUR (-2.21%)
-15.53 EUR (-15.53%)
-29.71 EUR (-29.71%)
-53.03 EUR (-53.03%)
-39.57 EUR (-39.57%)
-60.23 EUR (-60.23%)
-82.63 EUR (-82.63%)
-50.40 EUR (-50.40%)
About Nanobiotix
Market Capitalization 160.44M
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
| Headquarters (address) |
60 rue de Wattignies Paris 75012 France |
| Phone | 33 1 40 26 04 70 |
| Website | https://www.nanobiotix.com |
| Employees | 110 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | NANO |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 3.06 - 7.93 |
| Market Capitalization | 160.44M |
| P/E trailing | -2.87 |
| P/E forward | -3.04 |
| Price/Sale | 3.80 |
| Beta | 1.40 |
| EPS | -0.740 |
| EPS France (ID:70, base:331) | 3.06 |